Vector Laboratories Acquires Quanta BioDesign

Ampersand Capital Partners Acquires Nektar Therapeutics' PEG Reagent Manufacturing Business, Launches Gannet BioChem

December 2, 2024

Biotechnology

Ampersand Capital Partners has completed the acquisition of Nektar Therapeutics' PEGylation reagent manufacturing business and launched the new Ampersand portfolio company, Gannet BioChem, operating from a 124,000 sq. ft. FDA‑inspected facility in Huntsville, Alabama. The transaction represents a divestiture by Nektar and creates an independent specialty CDMO focused on development, scaling, and GMP production of polyethylene glycol (PEG) reagents for clinical and commercial biopharmaceutical customers.

Gannet BioChem Acquires Laysan Bio

January 22, 2026

Biotechnology

Gannet BioChem, a PE-backed specialty CDMO, has acquired Laysan Bio, a maker of activated polyethylene glycol (PEG) reagents based in Arab, Alabama. The add-on expands Gannet BioChem's activated polymer and bioconjugation capabilities, strengthening its ability to support partners from early development through GMP manufacturing.

Biosynth Acquires celares to Expand Bioconjugation and Polymer Drug Delivery Capabilities

July 11, 2023

Biotechnology

Biosynth, a Switzerland-based supplier of critical raw materials and manufacturing services, acquired Berlin-based celares, a developer and manufacturer of bioconjugates, activated PEGs and polymer-based drug delivery excipients. The acquisition strengthens Biosynth's capabilities in conjugate vaccines and bioconjugate drugs and adds GMP bioconjugation and PEGylation manufacturing in Berlin to its service offering.

Agilent Technologies Acquires BIOVECTRA for $925M

July 22, 2024

Pharmaceuticals

Agilent Technologies has acquired BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO), for $925 million. The acquisition — a purchase from H.I.G. Capital — expands Agilent's CDMO capabilities across biologics, HPAPIs, pDNA/mRNA and LNP formulation, and integrates BIOVECTRA into Agilent's Diagnostics and Genomics Group.

Vector Laboratories Acquires Click Chemistry Tools and Fluoroprobes

March 6, 2023

Biotechnology

Vector Laboratories, a portfolio company of Thompson Street Capital Partners, has acquired Click Chemistry Tools (Scottsdale, AZ) and Fluoroprobes to expand its manufacturing, bioconjugation and labeling capabilities. The add-on acquisitions, with terms undisclosed, are intended to accelerate commercialization of protein detection technologies and increase security of supply for biopharma, diagnostics and life-science customers.

Leinco Technologies Acquires QED Biosciences from Genovis

September 3, 2024

Biotechnology

Leinco Technologies, a portfolio company backed by Ampersand Capital Partners, has acquired Genovis-owned QED Biosciences to expand its catalog of antibodies, recombinant proteins and IVD raw materials. The deal transfers Genovis' antibody business to Leinco and strengthens Leinco's antibody development and IVD support capabilities for research and diagnostics customers worldwide.